deltatrials
Completed PHASE2 NCT00828009

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Lung Cancer
Interventions Tecemotide bevacizumab carboplatin cyclophosphamide paclitaxel radiotherapy
Updated 11 times since 2017 Last updated: Jun 21, 2023 Started: Jan 17, 2011 Primary completion: Aug 20, 2018 Completion: May 22, 2019

This PHASE2 trial investigates Lung Cancer and is currently completed. ECOG-ACRIN Cancer Research Group leads this study, which shows 11 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Aug 2023 [monthly]

    Completed PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 6 earlier versions

  1. Apr 2019 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  5. Feb 2017 — Nov 2017 [monthly]

    Unknown Status PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ECOG-ACRIN Cancer Research Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States, Ames, United States, Bloomington, United States, Boston, United States, Canton, United States, Carthage, United States, Charleston, United States, Chicago, United States, Cleveland, United States, Clive, United States and 53 more location s